[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351118-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351118-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","larotrectinib-in-patients-with-tumors-with-ntrk-fusions-results-from-the-nci-match-ecog-acrin-trial-subprotocol-eay131-z1e","Larotrectinib in Patients With Tumors With NTRK Fusions - Results From the NCI-MATCH ECOG-ACRIN Trial - Subprotocol EAY131-Z1E","","Recurrent NTRK fusions in neurotrophic tropomyosin receptor kinase (NTRK) are established oncogenic drivers across human cancers. Subprotocol Z1E of the NCI-MATCH trial evaluated larotrectinib, a selective inhibitor of all three TRK proteins, for efficacy and safety in TRK fusion–positive cancers. Solid-tumor and lymphoma patients progressed on standard therapy, received larotrectinib 100 mg twice daily, and were assessed with ORR as the primary endpoint alongside survival and safety measures.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/larotrectinib-in-patients-with-tumors-with-ntrk-fusions-results-from-the-nci-match-ecog-acrin-trial-subprotocol-eay131-z1e/351118/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/larotrectinib-in-patients-with-tumors-with-ntrk-fusions-results-from-the-nci-match-ecog-acrin-trial-subprotocol-eay131-z1e/351118.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary objective of NCI-MATCH subprotocol Z1E?","Question",{"text":63,"@type":64},"To evaluate whether larotrectinib provides clinical benefit for TRK fusion–positive cancers independent of histology, with efficacy assessed by objective response rate.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was larotrectinib administered and what were the key secondary endpoints?",{"text":68,"@type":64},"Patients received larotrectinib 100 mg twice daily until disease progression or unacceptable toxicity. Secondary endpoints included progression-free survival at 6 months, overall progression-free survival, overall survival, and safety.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main efficacy and safety findings?",{"text":72,"@type":64},"Among 12 centrally confirmed NTRK fusion–positive patients, the ORR was 75% with median PFS of 14.4 months and median OS of 23.9 months. Adverse events were predominantly grade 1, with no clinically significant toxicities reported.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351118,1790169438,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Original Reports | Targeted Drug Therapy  \nLarotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E  \nNeal Akhave, MD1  ; Zihe Song, MS2; David S. Hong, MD1  ; Robert J. Gray, PhD2  ; Victoria Wang, PhD2; Lisa M. McShane, PhD3  ; Larry V. Rubinstein, PhD3  ; David R. Patton, BS4  ; P. Mickey Williams, PhD5; Stanley R. Hamilton, MD6  ; Naoko Takebe, MD, PhD7  ; James V. Tricoli, PhD8  ; Barbara A. Conley, MD8  ; Carlos L. Arteaga, MD9; Lyndsay N. Harris, MD8  ; Peter J. O’Dwyer, MD10  ; Alice P. Chen, MD7  ; and Keith T. Flaherty, MD11   \nDOI [https://doi.org/10.1200/PO-25-00612](https://doi.org/10.1200/PO-25-00612)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Recurrent chromosomal fusions in neurotrophic tropomyosin receptor kinase (NTRK) have been reported as an oncogenic driver across human cancer. Herein, we report results from subprotocol Z1E of the NCI-MATCH (Molecular Analysis for Therapy Choice) trial investigating the efﬁcacy and safety of larotrectinib, a highly selective inhibitor of all three TRK proteins, in TRK fusion–positive cancers. |\n| METHODS | From August 21, 2017, to July 8, 2021, patients with solid tumors or lymphomas progressing on standard therapy were genomically proﬁled and enrolled toNCIMATCH, a genomically driven, signal-seeking, precision medicine platform trial. They were assigned to subprotocol Z1E if a NTRK fusion–positive tumor was identiﬁed. Patients received larotrectinib 100 mg twice daily until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) . Secondary end points included progression-free survival (PFS) at 6 months, PFS, overall survival (OS), and safety. |\n| RESULTS | In total, 12 patients with centrally conﬁrmed NTRK fusion–positive tumors were treated with larotrectinib across six distinct tumor histologies. The ORR was 75%(90% CI, 47 .3% to 92 . 8%) with median PFS andOS of 14.4 (90% CI, 8.48 to not reached [NR]) months and 23.9 (90% CI, 11.1 to NR) months, respectively. Treatment was well tolerated, with adverse events predominantly being grade 1. |\n| CONCLUSION | NCI-MATCH subprotocol Z1E demonstrates that larotrectinib offers clinically signiﬁcant beneﬁt with marked ORR across NTRK fusion–positive tumors with no clinically signiﬁcant toxicities. These ﬁndings support the rationale for the US Food and Drug Administration’s tissue-agnostic approval of larotrectinib for NTRK fusion–positive tumors. Our ﬁndings demonstrate the necessity of including NTRK1 , NTRK2 , and NTRK3 within comprehensive molecular assays of cancer to navigate patients to an easily administered and highly effective therapy. |\n\nACCOMPANYING CONTENT  \n Data Sharing Statement  \n Data Supplement  \n Protocol  \nAccepted January 13, 2026 Published February 20, 2026  \nJCO Precis Oncol 10:e2500612 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nNeurotrophic receptor tyrosine kinase genes, NTRK1 , NTRK2 , and NTRK3 , encode for tropomyosin receptor kinase (TRK) proteins TRKA, TRKB, and TRKC, respectively, and are expressed across a variety of tissue types. These proteins are involved with neuronal development, maintenance, and protection.1 Activation of TRK by its respective ligand leads to dimerization and activation of downstream signaling, including PI3 kinase and mitogen-activated protein kinase pathways, leading to growth and survival.2  \nLigand-independent constitutive activation of TRK proteins via NTRK gene rearrangements has been reported across human cancers, including both common and rare tumor histologies, and independent of tissue of origin.3-8 Rearrangements in NTRK are rare with a prevalence of \u003C1% of all human cancers,9 including the common cancers such as breast, lung, and colon carcinomas. Prevalence is increased in rare tumors, such as secretory carcinomas of the salivary gland or breast ","cbCaitiQqh9A7dcy","https://ap.wps.com/l/cbCaitiQqh9A7dcy","pdf",1357797,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Context and Rationale\n## Key Objective\n## Knowledge Generated\n## Relevance\n# Introduction\n## Biology of NTRK and TRK Signaling\n## Prevalence and Oncogenic Drivers\n## Trial Overview (NCI-MATCH)","[{\"question\":\"What was the primary objective of NCI-MATCH subprotocol Z1E?\",\"answer\":\"To evaluate whether larotrectinib provides clinical benefit for TRK fusion–positive cancers independent of histology, with efficacy assessed by objective response rate.\"},{\"question\":\"How was larotrectinib administered and what were the key secondary endpoints?\",\"answer\":\"Patients received larotrectinib 100 mg twice daily until disease progression or unacceptable toxicity. Secondary endpoints included progression-free survival at 6 months, overall progression-free survival, overall survival, and safety.\"},{\"question\":\"What were the main efficacy and safety findings?\",\"answer\":\"Among 12 centrally confirmed NTRK fusion–positive patients, the ORR was 75% with median PFS of 14.4 months and median OS of 23.9 months. Adverse events were predominantly grade 1, with no clinically significant toxicities reported.\"}]","Larotrectinib in Patients With Tumors With NTRK Fusions - Results From the NCI-MATCH ECOG-ACRIN Trial - Subprotocol EAY131-Z1E | PDF",1790092691,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/913b44ecf5485c93efd0452760670bb8.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/295dff9e9c057b13fa617f5f1387d960.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/421d50f05d6171cd2fd80295de857499.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0893c547181fb3fb6e735b3fffd51b8d.webp",980,1311]